Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers

Cancer

Volumn 98, Issue 8, 2003, Pages 1635-1642

  Habuchi, Tomonori ^a   Kamoto, Toshiyuki ^a   Hara, Isao ^b   Kawai, Koji ^c   Nakao, Masahiro ^d   Nonomura, Norio ^e   Kobayashi, Takashi ^a   Ogawa, Osamu ^a   Kamidono, Sadao ^b   Akaza, Hideyuki ^c   Okuyama, Akihiko ^e   Kato, Tetsuro ^f   Miki, Tsuneharu ^d  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

fetoprotein (AFP); Chemotherapy; Germ cell carcinoma; Human chorionic gonadotropin (HCG); Salvage surgery

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NEDAPLATIN; PACLITAXEL; PEPLEOMYCIN; TUMOR MARKER; VINBLASTINE;

ADULT; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; GERM CELL TUMOR; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141923872     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11711     Document Type: Review

References (19)

1. Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. Semin Oncol. 1992;19:148-158.
2. Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a Phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994;12: 1223-1231.
3. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996; 14:2638-2645.
4. Porcu P, Bhatia S, Sharma M, Einhorn LH. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol. 2000;18:1181-1186.
5. Miki T, Mizutani Y, Nonomura N, et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer. 2002;95:1879-1885.
6. Wood DP Jr., Herr HW, Motzer RJ, et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer. 1992;70:2354-2357.
7. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11: 324-329.
8. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology. 1994;43:74-80.
9. Kisbenedek L, Bodrogi I, Szeldeli P, Baki M, Tenke P, Horti J. Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy. Int Urol Nephrol. 1995;27:325-329.
10. Albers P, Ganz A, Hannig E, Miersch WD, Muller SC. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164:381-384.
11. Greene FL, Page DL, Fleming ID, et al. editors. AJCC cancer staging manual, 6th edition. New York: Springer-Verlag, 2002:317-322.
12. Germa JR, Llanos M, Tabernero JM, Mora J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer. 1993;72:2491-2494.
13. Kamoto T, Satomura S, Yoshiki T, et al. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol. 2002;32:472-476.
14. Germa JR, Arcusa A, Casamitjana R. False elevations of human chorionic gonadotropin associated to iatrogenic hypogonadism in gonadal germ cell tumors. Cancer. 1987;60: 2489-2493.
15. Hejase MJ, Donohue JP, Foster RS, et al. Post-chemotherapy resection of nonseminomatous germ cell testicular tumors metastatic to the mediastinum. J Urol. 1996;156:1345-1348.
16. Bosl GJ, Gluckman R, Geller NL, et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol. 1986;4:1493-149.
17. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988;6:1031-1040.
18. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546-2552.
19. Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur J Cancer. 1992;28:86-91.